Icon Plc $ICLR is Trinity Street Asset Management LLP’s 5th Largest Position

Trinity Street Asset Management LLP lifted its position in Icon Plc (NASDAQ:ICLR – Free Report) by 12.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,208,148 shares of the medical research company’s stock after buying an additional 135,720 shares during the quarter. Icon makes up about 9.2% of Trinity Street Asset Management LLP’s holdings, making the stock its 5th largest holding. Trinity Street Asset Management LLP’s holdings in Icon were worth $133,694,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Toth Financial Advisory Corp purchased a new stake in shares of Icon in the 4th quarter valued at approximately $27,000. EFG International AG purchased a new position in Icon during the 4th quarter worth approximately $27,000. Ameriflex Group Inc. purchased a new position in Icon during the 3rd quarter worth approximately $33,000. Abound Financial LLC acquired a new stake in Icon during the 4th quarter valued at $54,000. Finally, Johnson Financial Group Inc. acquired a new stake in Icon during the 3rd quarter valued at $71,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Get Icon alerts:

Icon Stock Up 0.4%

ICLR stock opened at $173.69 on Wednesday. The company has a 50 day moving average of $131.87 and a two-hundred day moving average of $137.82. The company has a market cap of $13.30 billion, a price-to-earnings ratio of 30.91, a PEG ratio of 8.52 and a beta of 1.26. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR – Get Free Report) last posted its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.43 by $0.07. Icon had a net margin of 5.35% and a return on equity of 8.73%. The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the previous year, the company posted $3.43 EPS. Icon’s revenue was up 2.5% on a year-over-year basis. On average, equities analysts anticipate that Icon Plc will post 9.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ICLR shares. Weiss Ratings cut Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 price target on Icon in a research report on Thursday, May 28th. BMO Capital Markets increased their price objective on Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Robert W. Baird increased their price objective on Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Finally, UBS Group set a $160.00 target price on Icon in a research note on Wednesday, June 24th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $173.19.

View Our Latest Research Report on Icon

About Icon

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Recommended Stories

• Five stocks we like better than Icon
• NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
• Amazon Could Be About to Reap the Rewards of a Software Spending Boom
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR – Free Report).

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.